Financial Performance - Revenue for Q2 2025 increased 128% year over year to approximately $212 thousand, compared to $93 thousand in Q2 2024[7] - First half 2025 revenue increased 103% to approximately $355 thousand, compared to $175 thousand in the first half of 2024[7] - Sequential quarter over quarter sales increased 48%[1] - Net loss for Q2 2025 was approximately $5.4 million, with $3.2 million being non-cash charges[7] - Total assets on June 30, 2025, were $25.6 million, and total shareholders' equity was $6.5 million[7] - Cash position on June 30, 2025, was $838 thousand[7] Product Development and Regulatory Approvals - The CE Mark for the LockeT product was received, with sales expected to start in Europe in Q3 2025[1] - Significant clinical data presented at the Heart Rhythm Society symposium showed VIVO's accuracy over 94% and long-term procedural success over 83%[1] - The acquisition of Cardionomic's heart failure assets was completed by a newly formed 82%-owned subsidiary, Cardionomix[1] - A majority-owned joint venture, Kardionav, was formed to develop an implant-based software product for treating ventricular tachyarrhythmia[1]
RA MEDICAL SYSTE(RMED) - 2025 Q2 - Quarterly Results